Q-omics provides the consensus-scored RPS27P25 profile across patient tissues and cancer cell-line models. RPS27P25 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPS27P25 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, RPS27P25 RNA expression shows 11,951 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, and LSCC as cancer lineages where RPS27P25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS27P25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS27P25 survival associations across molecular data types. RPS27P25 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS27P25 RNA expression–survival associations across cancer types. High RPS27P25 expression shows unfavorable associations in LIHC and LGG, but favorable associations in PAAD, KICH, BRCA and LUSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RPS27P25 RNA expression.
This table summarizes RPS27P25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS27P25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS27P25 shows lower tumor expression in KIRP and KIRC and higher tumor expression in LIHC, UCEC, LUSC and HNSC. The LIHC box plot shows higher RPS27P25 RNA expression in tumor versus normal tissue (log2 FC = +0.135, t-test p < 0.001).
This table shows molecular features associated with RPS27P25 in patient tissues and cancer cell lines. In patient samples, RPS27P25 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
